Brexit: Discussing the impact of the UK’s departure from the European Union

The United Kingdom (UK) will leave the European Union (EU) on 29th March 2019. The steps and measures pharmaceutical firms take at this stage will be critical to post-Brexit preparedness, failure to take action could ultimately impact the supply of medicines and patient safety.

Recipharm established a Brexit taskforce with the aim of closely monitoring developments and ensuring the impact on its customers was minimised.

However, there remains little guidance on how the UK’s departure will affect the pharmaceutical industry, meaning pharmaceutical firms are initiating and implementing their own short-term solutions, such as stockpiling, in preparation for the looming deadline.

In this article with PharmaNETWORK, Thomas Beck, senior vice president, at Recipharm explores the challenges of the UK leaving the EU and the impact it will have on pharmaceutical companies. He also provides insight into the steps Recipharm is taking to ensure it is prepared for any outcome.

For the full article see page 60-62 here: http://www.pharmanetwork.digital/